1. Home
  2. SMTI vs LUNG Comparison

SMTI vs LUNG Comparison

Compare SMTI & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sanara MedTech Inc.

SMTI

Sanara MedTech Inc.

HOLD

Current Price

$24.52

Market Cap

186.9M

Sector

Health Care

ML Signal

HOLD

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

HOLD

Current Price

$2.28

Market Cap

63.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SMTI
LUNG
Founded
1982
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Industrial Specialties
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
186.9M
63.6M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
SMTI
LUNG
Price
$24.52
$2.28
Analyst Decision
Strong Buy
Buy
Analyst Count
2
7
Target Price
$41.00
$6.81
AVG Volume (30 Days)
44.8K
1.0M
Earning Date
11-12-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$101,877,532.00
$91,664,000.00
Revenue This Year
$21.60
$9.21
Revenue Next Year
$16.70
$5.03
P/E Ratio
N/A
N/A
Revenue Growth
30.52
15.59
52 Week Low
$18.90
$1.31
52 Week High
$38.68
$9.37

Technical Indicators

Market Signals
Indicator
SMTI
LUNG
Relative Strength Index (RSI) 53.32 54.78
Support Level $24.00 $2.16
Resistance Level $25.41 $2.65
Average True Range (ATR) 1.17 0.20
MACD 0.34 -0.02
Stochastic Oscillator 55.71 45.71

Price Performance

Historical Comparison
SMTI
LUNG

About SMTI Sanara MedTech Inc.

Sanara MedTech Inc is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the chronic and surgical wound and skincare markets. Its portfolio of products and services allows it to deliver comprehensive wound and skincare solutions for patients in all care settings, including acute and post-acute. Its surgical wound care products are CellerateRX Surgical Activated Collagen. Its chronic wound care products are BIAKOS Skin and Wound Cleanser, and BIAKOS Skin and Wound Gel.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.

Share on Social Networks: